PCSK9 Inhibitor Market Report 2026

PCSK9 Inhibitor Market Overview

• PCSK9 Inhibitor market size has reached to $3.24 billion in 2025 • Expected to grow to $8.28 billion in 2030 at a compound annual growth rate (CAGR) of 20.6% • Growth Driver: Surge In Hyperlipidemia Prevalence Fueling The Growth Of The Market Due To Aging Populations And Rising Cholesterol Rates • Market Trend: Innovative Base Editing Therapy Shows Deep Low-Density Lipoprotein Cholesterol Reduction In Early Human Study • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under PCSK9 Inhibitor Market?

PCSK9 inhibitors refer to medications lowering LDL cholesterol by preventing PCSK9 protein from degrading LDL receptors on liver cells. By blocking PCSK9, these inhibitors enhance the liver’s ability to remove low-density lipoprotein cholesterol, thereby lowering blood cholesterol levels and reducing the risk of cardiovascular diseases. The main drug types of PCSK9 inhibitors include alirocumab, evolocumab, inclisiran, bococizumab, and others. Alirocumab refers to a fully human monoclonal antibody that inhibits PCSK9 to lower low-density lipoprotein cholesterol levels in patients with hypercholesterolemia. The multiple routes of administration are oral, subcutaneous injection, and intravenous injection. The modality is divided into fully humanized monoclonal antibodies and small interfering RNA (siRNA). There are various applications, such as hypercholesterolemia, hyperlipidemia, cardiovascular disease prevention, and familial hypercholesterolemia, and there are sales channels into hospitals, specialty clinics, retail pharmacies, and online pharmacies.

What Is The PCSK9 Inhibitor Market Growth Forecast?

The pcsk9 inhibitor market size is expected to see exponential growth in the next few years. It will grow to $8.28 billion in 2030 at a compound annual growth rate (CAGR) of 20.6%. The growth in the forecast period can be attributed to launch of inclisiran and other siRNA therapies, expansion of combination therapy options, increasing adoption of personalized medicine approaches, rising healthcare expenditure on cardiovascular disease management, development of digital patient monitoring and adherence programs. Major trends in the forecast period include rising prevalence of hypercholesterolemia and cardiovascular diseases, increased adoption of subcutaneous and intravenous administration routes, development of biosimilars and combination therapies, growing investment in personalized lipid-lowering treatments, expansion of specialty clinics and hospital-based pcsk9 therapy programs.

Global PCSK9 Inhibitor Market Segmentation

1) By Drug Type: Alirocumab, Evolocumab, Inclisiran, Bococizumab, Other Types 2) By Route of Administration: Oral, Subcutaneous Injection, Intravenous Injection 3) By Modality: Fully-Humanized Monoclonal Antibodies, Small Interfering RNA (siRNA) 4) By Application: Hypercholesterolemia, Hyperlipidemia, Cardiovascular Disease Prevention, Familial Hypercholesterolemia 5) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Alirocumab: Dosage Forms, Indications, Administration Frequency 2) By Evolocumab: Dosage Forms, Indications, Administration Frequency 3) By Inclisiran: Dosage Forms, Indications, Dosing Schedule 4) By Bococizumab: Dosage Forms, Indications, Development Status 5) By Other Types: Emerging PCSK9 Inhibitors, Combination Therapies, Biosimilars Or Generics

What Is The Driver Of The PCSK9 Inhibitor Market?

The increasing hyperlipidemia prevalence is expected to propel the growth of the PCSK9 inhibitor market going forward. Hyperlipidemia is a condition characterized by elevated levels of lipids, including cholesterol and triglycerides, in the bloodstream, increasing the risk of cardiovascular diseases. The rise in hyperlipidemia prevalence is due to the aging populations, as cholesterol levels tend to increase significantly with age, especially after 45 years. PCSK9 inhibitors help hyperlipidemia by enhancing the liver’s ability to remove excess LDL cholesterol from the bloodstream, leading to improved lipid profiles. For instance, in December 2023, according to the Australian Bureau of Statistics, an Australia-based government agency, high cholesterol rates are rising steeply from 1.1% in ages 18–34 to 29.0% in those 75 and older. Therefore, the increasing hyperlipidemia prevalence is propelling the growth of the PCSK9 inhibitor industry.

Key Players In The Global PCSK9 Inhibitor Market

Major companies operating in the pcsk9 inhibitor market are Sanofi S.A, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Innovent Biologics Inc., Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Verve Therapeutics Inc., LIB Therapeutics LLC, Vaxxinity Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shenyang Xinlitai Pharmaceutical Co. Ltd.

Global PCSK9 Inhibitor Market Trends and Insights

Major companies operating in the PCSK9 inhibitor market are focusing on developing innovative solutions, such as in vivo gene therapy, to create long-lasting or one-time treatments that permanently lower LDL cholesterol levels in patients with high cardiovascular risk. In vivo gene therapy refers to the direct delivery of genetic material into a patient’s body to modify or replace faulty genes within targeted cells, enabling therapeutic effects at the source of disease. For instance, in April 2025, Verve Therapeutics Inc., a US-based clinical-stage company, announced early results from its Heart-2 Phase 1b trial of VERVE-102. This study targets patients with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD), conditions needing significant and lasting LDL cholesterol reductions. A single dose of VERVE-102 caused dose-dependent declines in both PCSK9 protein and LDL-C levels. In the 0.6 mg/kg group, participants experienced an average low-density lipoprotein cholesterol drop of 53%, with some reaching a maximum reduction of 69%. These findings highlight VERVE-102’s potential as a powerful cholesterol-lowering therapy.

What Are Latest Mergers And Acquisitions In The PCSK9 Inhibitor Market?

In March 2024, Lib Therapeutics, a US-based biopharmaceutical company, partnered with Hasten Biopharmaceuticals to commercialize its PCSK9 inhibitor LIB003 in China. With this partnership, LIB Therapeutics aims to accelerate the clinical development and regulatory approval of lerodalcibep in China by leveraging Hasten Biopharmaceuticals' expertise in navigating the country's regulatory landscape and market dynamics, ultimately advancing a novel therapeutic option for patients with hypercholesterolemia. Hasten Biopharmaceuticals Co., Ltd. is a China-based company specializing in clinical development and drug manufacturing and advancing the clinical trial application for lerodalcibep.

Regional Insights

North America was the largest region in the PCSK9 inhibitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the PCSK9 Inhibitor Market?

The PCSK9 inhibitor market consists of sales of monoclonal antibodies, sirna therapies, small molecule inhibitors, and peptide-based inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the PCSK9 Inhibitor Market Report 2026?

The pcsk9 inhibitor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pcsk9 inhibitor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.